129 related articles for article (PubMed ID: 20133511)
1. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
2. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.
Gotzkowsky SK; Kumar P; Mottola D; Laliberte K
J Cardiovasc Pharmacol; 2013 May; 61(5):444-51. PubMed ID: 23429588
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
5. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.
Lim A; Wang-Smith L; Kates J; Laurent A; Kumar P; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):450-5. PubMed ID: 23927483
[TBL] [Abstract][Full Text] [Related]
6. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
Peterson L; Marbury T; Marier J; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):518-23. PubMed ID: 24033615
[TBL] [Abstract][Full Text] [Related]
9. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
[TBL] [Abstract][Full Text] [Related]
10. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
12. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
13. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Suleman N; Frost AE
Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
16. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
17. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
18. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess G; Hoogkamer H; Collings L; Dingemanse J
Eur J Clin Pharmacol; 2008 Jan; 64(1):43-50. PubMed ID: 18040672
[TBL] [Abstract][Full Text] [Related]
19. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
